Abstract
The combination of methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) has been the standard therapy for transitional cell carcinoma for over a decade. Despite evidence that MVAC can improve outcome in comparison with single drugs or other combinations in this disease, only a small fraction of patients (less than 4%) become long-term survivors, and the regimen is quite toxic. Attempts to improve upon the MVAC regimen have partially ameliorated its toxicity, but they have not clearly improved outcome. Recently, a number of new chemotherapeutic agents have become available. This report summarizes the current experience with these agents and combinations.
| Original language | English |
|---|---|
| Pages (from-to) | 379-385 |
| Number of pages | 7 |
| Journal | Current Oncology Reports |
| Volume | 2 |
| Issue number | 5 |
| DOIs | |
| State | Published - 2000 |
Keywords
- Antimetabolites, Antineoplastic/therapeutic use
- Antineoplastic Agents, Phytogenic/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Bridged-Ring Compounds/therapeutic use
- Carcinoma, Transitional Cell/drug therapy
- Cisplatin/administration & dosage
- Deoxycytidine/analogs & derivatives
- Doxorubicin/administration & dosage
- Gallium/therapeutic use
- Gemcitabine
- Humans
- Ifosfamide/therapeutic use
- Methotrexate/administration & dosage
- Neoplasm Metastasis
- Taxoids
- Urinary Bladder Neoplasms/drug therapy
- Vinblastine/administration & dosage
